Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Multi-Outbreak, Randomized, Controlled Safety and Efficacy Study of Investigational Therapeutics for the Treatment of Patients With Ebola Virus Disease

Trial Profile

A Multicenter, Multi-Outbreak, Randomized, Controlled Safety and Efficacy Study of Investigational Therapeutics for the Treatment of Patients With Ebola Virus Disease

Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 18 Feb 2019

At a glance

  • Drugs MAb 114 (Primary) ; Porgaviximab (Primary) ; Remdesivir (Primary) ; REGN 3470/3471/3479
  • Indications Ebola virus infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 14 Feb 2019 Planned initiation date (estimated date for recruitment of the first subject) changed from 01 Feb 2019 to 20 Feb 2019.
    • 26 Jan 2019 Planned initiation date (estimated date for recruitment of the first subject) changed from 31 Jan 2019 to 1 Feb 2019.
    • 25 Jan 2019 Planned initiation date (estimated date for recruitment of the first subject) changed from 01 Jan 2019 to 31 Jan 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top